Title:
Ph2 SKB264 + Pembro in Select Solid Tumors
View
Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)
Indication:
Cervical Cancer
Location:
Texas Oncology-Horizon Circle
Phase: II
Title:
Ph2 SKB264 + Pembro in Select Solid Tumors
View
Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)
Indication:
Cervical Cancer
Location:
Texas Oncology-Hamilton
Phase: II
Title:
Ph2 SKB264 + Pembro in Select Solid Tumors
View
Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)
Indication:
Cervical Cancer
Location:
Texas Oncology-Waco
Phase: II
Title:
Ph2 SKB264 + Pembro in Select Solid Tumors
View
Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)
Indication:
Cervical Cancer
Location:
Texas Oncology-Clifton
Phase: II
Title:
Ph2 Girdes Endo Carcinoma
View
Description: A PHASE II SINGLE-ARM STUDY OF GIREDESTRANT IN PATIENTS WITH GRADE 1 ENDOMETRIAL CANCER (CO44195)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Waco
Phase: II
Title:
Ph2 Girdes Endo Carcinoma
View
Description: A PHASE II SINGLE-ARM STUDY OF GIREDESTRANT IN PATIENTS WITH GRADE 1 ENDOMETRIAL CANCER (CO44195)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Clifton
Phase: II
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Horizon Circle
Phase: II
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Hamilton
Phase: II
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Waco
Phase: II
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Clifton
Phase: II
Title:
Ph2 ONC-392 Pembro Ovarian PROC (PRESERVE-004)
View
Description: Phase 2 Randomized Open-label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of Patients with Platinum Resistant Ovarian Cancer (PROC) (PRESERVE-004 MK-3475-E24 GOG-3081)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Waco
Phase: II
Title:
Ph2 ONC-392 Pembro Ovarian PROC (PRESERVE-004)
View
Description: Phase 2 Randomized Open-label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of Patients with Platinum Resistant Ovarian Cancer (PROC) (PRESERVE-004 MK-3475-E24 GOG-3081)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Clifton
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Leukemia
Location:
Texas Oncology-Horizon Circle
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Leukemia
Location:
Texas Oncology-Hamilton
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Leukemia
Location:
Texas Oncology-Waco
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Leukemia
Location:
Texas Oncology-Clifton
Phase: II
Title:
Ph2 Platform Substudy-01: patients w/ no prior systemic treatment for metastatic NSCLC
View
Description: A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) Substudy-01: Patients With No Prior Systemic Treatment for Metastatic NSCLC (GS-US-624-6376-01)
Indication:
Lung Cancer
Location:
Texas Oncology-Horizon Circle
Phase: II
Title:
Ph2 Platform Substudy-01: patients w/ no prior systemic treatment for metastatic NSCLC
View
Description: A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) Substudy-01: Patients With No Prior Systemic Treatment for Metastatic NSCLC (GS-US-624-6376-01)
Indication:
Lung Cancer
Location:
Texas Oncology-Hamilton
Phase: II
Title:
Ph2 Platform Substudy-01: patients w/ no prior systemic treatment for metastatic NSCLC
View
Description: A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) Substudy-01: Patients With No Prior Systemic Treatment for Metastatic NSCLC (GS-US-624-6376-01)
Indication:
Lung Cancer
Location:
Texas Oncology-Waco
Phase: II
Title:
Ph2 Platform Substudy-01: patients w/ no prior systemic treatment for metastatic NSCLC
View
Description: A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) Substudy-01: Patients With No Prior Systemic Treatment for Metastatic NSCLC (GS-US-624-6376-01)
Indication:
Lung Cancer
Location:
Texas Oncology-Clifton
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Lymphomas
Location:
Texas Oncology-Horizon Circle
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Lymphomas
Location:
Texas Oncology-Hamilton
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Lymphomas
Location:
Texas Oncology-Waco
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Lymphomas
Location:
Texas Oncology-Clifton
Phase: II
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Horizon Circle
Phase: II
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Hamilton
Phase: II
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Waco
Phase: II
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Clifton
Phase: II
Title:
Ph2 ONC-392 Pembro Ovarian PROC (PRESERVE-004)
View
Description: Phase 2 Randomized Open-label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of Patients with Platinum Resistant Ovarian Cancer (PROC) (PRESERVE-004 MK-3475-E24 GOG-3081)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Waco
Phase: II
Title:
Ph2 ONC-392 Pembro Ovarian PROC (PRESERVE-004)
View
Description: Phase 2 Randomized Open-label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of Patients with Platinum Resistant Ovarian Cancer (PROC) (PRESERVE-004 MK-3475-E24 GOG-3081)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Clifton
Phase: II
Title:
Ph2 SKB264 + Pembro in Select Solid Tumors
View
Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Horizon Circle
Phase: II
Title:
Ph2 SKB264 + Pembro in Select Solid Tumors
View
Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Hamilton
Phase: II
Title:
Ph2 SKB264 + Pembro in Select Solid Tumors
View
Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Waco
Phase: II
Title:
Ph2 SKB264 + Pembro in Select Solid Tumors
View
Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Clifton
Phase: II
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Horizon Circle
Phase: II
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Hamilton
Phase: II
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Waco
Phase: II
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Clifton
Phase: II
Title:
Ph2 ONC-392 Pembro Ovarian PROC (PRESERVE-004)
View
Description: Phase 2 Randomized Open-label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of Patients with Platinum Resistant Ovarian Cancer (PROC) (PRESERVE-004 MK-3475-E24 GOG-3081)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Waco
Phase: II
Title:
Ph2 ONC-392 Pembro Ovarian PROC (PRESERVE-004)
View
Description: Phase 2 Randomized Open-label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of Patients with Platinum Resistant Ovarian Cancer (PROC) (PRESERVE-004 MK-3475-E24 GOG-3081)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Clifton
Phase: II
Title:
Ph2 SKB264 + Pembro in Select Solid Tumors
View
Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)
Indication:
Prostate Cancer
Location:
Texas Oncology-Horizon Circle
Phase: II
Title:
Ph2 SKB264 + Pembro in Select Solid Tumors
View
Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)
Indication:
Prostate Cancer
Location:
Texas Oncology-Hamilton
Phase: II
Title:
Ph2 SKB264 + Pembro in Select Solid Tumors
View
Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)
Indication:
Prostate Cancer
Location:
Texas Oncology-Waco
Phase: II
Title:
Ph2 SKB264 + Pembro in Select Solid Tumors
View
Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)
Indication:
Prostate Cancer
Location:
Texas Oncology-Clifton
Phase: II
Title:
Ph2 Tumor-Agnostic Precision TAPISTRY
View
Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)
Indication:
Solid Tumors
Location:
Texas Oncology-Horizon Circle
Phase: II
Title:
Ph2 Tumor-Agnostic Precision TAPISTRY
View
Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)
Indication:
Solid Tumors
Location:
Texas Oncology-Hamilton
Phase: II
Title:
Ph2 Tumor-Agnostic Precision TAPISTRY
View
Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)
Indication:
Solid Tumors
Location:
Texas Oncology-Waco
Phase: II
Title:
Ph2 Tumor-Agnostic Precision TAPISTRY
View
Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)
Indication:
Solid Tumors
Location:
Texas Oncology-Clifton
Phase: II
Title:
STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes
View
Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)
Indication:
Solid Tumors
Location:
Texas Oncology-Horizon Circle
Phase: II
Title:
STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes
View
Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)
Indication:
Solid Tumors
Location:
Texas Oncology-Hamilton
Phase: II
Title:
STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes
View
Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)
Indication:
Solid Tumors
Location:
Texas Oncology-Waco
Phase: II
Title:
STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes
View
Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)
Indication:
Solid Tumors
Location:
Texas Oncology-Clifton
Phase: II
Title:
Ph2 SKB264 + Pembro in Select Solid Tumors
View
Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Horizon Circle
Phase: II
Title:
Ph2 SKB264 + Pembro in Select Solid Tumors
View
Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Hamilton
Phase: II
Title:
Ph2 SKB264 + Pembro in Select Solid Tumors
View
Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Waco
Phase: II
Title:
Ph2 SKB264 + Pembro in Select Solid Tumors
View
Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Clifton
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Waldenström macroglobulinemia
Location:
Texas Oncology-Horizon Circle
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Waldenström macroglobulinemia
Location:
Texas Oncology-Hamilton
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Waldenström macroglobulinemia
Location:
Texas Oncology-Waco
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Waldenström macroglobulinemia
Location:
Texas Oncology-Clifton
Phase: II